SCHEMBL6661142

SCHEMBL6661142

Cc1ccncc1-n1ccc2cc(-c3ccccc3F)c(F)cc21

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.39
CYP19A1 P11511 1/20 0.38
CYP11B1 P15538 3/20 0.37
CYP11B2 P19099 3/20 0.37
CYP17A1 P05093 3/20 0.36
NOS2 P35228 1/20 0.34
MBNL1 Q9NR56 1/20 0.34
PDE10A Q9Y233 1/20 0.34
PTK2 Q05397 1/20 0.34
CYP1A2 P05177 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7104139 0.89 CYP11B1 (0.44) MAPTCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL6846187 0.85 MAPT (0.40) MAPTCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL6845932 0.85 CYP11B1 (0.46) MAPTCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL6847790 0.81 MAPT (0.36) MAPTCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL6660236 0.75 CYP19A1 (0.40) MAPTCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL6659082 0.75 CYP19A1 (0.47) MAPTCYP19A1PDE10A
SCHEMBL6662653 0.74 POLB (0.40) MAPTCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL6659366 0.73 CYP19A1 (0.47) MAPTCYP19A1CYP11B1CYP11B2PDE10A
SCHEMBL6653056 0.73 CYP11B1 (0.46) CYP19A1CYP11B1CYP11B2PDE10APTK2
SCHEMBL6654310 0.73 CYP11B1 (0.45) MAPTCYP19A1CYP11B1CYP11B2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed
EP-1432698-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027094-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 MAPT 1659/4885CYP19A1 9/4885CYP11B1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.